Most Read Articles
Dr. Joseph Delano Fule Robles, 05 Dec 2017

Results of a study conducted by the Chinese University of Hong Kong (CUHK) revealed that patients who recovered from hepatitis B virus (HBV) infection are still at risk for hepatocellular carcinoma (HCC). 

Dr. Joseph Delano Fule Robles, 11 Dec 2017

Societies that value autonomy and harmony tend to have higher alcohol consumption as compared with more conservative societies that value hierarchy and embeddedness, a recent study has shown. 

Tristan Manalac, 10 Dec 2017
Mirizzi Syndrome (MS) is a rare medical phenomenon in Singapore and its accurate diagnosis remains a challenge, reports a recent study, which also shows that less than 75 percent of patients are accurately diagnosed prior to surgery.
Kathlin Ambrose, 17 Apr 2015
Timely treatment of autoimmune hepatitis (AIH) is life saving, says an expert in autoimmune liver diseases.

AIT improves mortality, recurrence in HCC patients after curative treatment

02 Apr 2017

Adjuvant adoptive immunotherapy (AIT) for hepatocellular carcinoma (HCC) patients who have received therapy is both safe and effective for improving mortality rates and tumour recurrence, a new meta-analysis shows.

The Cochrane Library, Scopus, EMBASE and PubMed were searched for studies that investigated the effects of adjuvant AIT on HCC patients after curative treatments compared with either no interventions or control interventions. Those that considered advanced, unresectable or recurrent HCC were excluded.

The Newcastle-Ottawa and the Jadad scales were used to assess the quality of the non-randomized and observational trials, and randomized trials, respectively.

After applying the inclusion and exclusion criteria, eight studies (seven randomized controlled trials [RCT], one cohort study), corresponding to 949 treated and 912 untreated individuals, were included. Four of the RCTs had high methodological quality while three had low scores. The cohort study had a low risk of bias.

A fixed-effects model showed that, compared with curative therapies alone, adjuvant AIT was associated with improved mortality rates at 1 year (risk ratio [RR], 0.63; 95 percent CI, 0.50 to 0.78; p<0.001), 2 years (RR, 0.72; 0.63 to 0.83; p<0.001), 3 years (RR, 0.74; 0.65 to 0.83; p<0.001) and 5 years (RR, 0.88; 0.80 to 0.96; p=0.005).

Similarly, adjuvant AIT was associated with improvements in tumour recurrence rates at 1 year (RR, 0.80; 0.71 to 0.90; p=0.001), 2 years (RR, 0.80; 0.70 to 0.83; p<0.001), 3 years (RR, 0.86; 0.80 to 0.90; p<0.001) and 5 years (RR, 0.91; 0.85 to 0.97; p=0.004).

Finally, no serious adverse events or deaths were documented across the eight studies included. The most common adverse events were chills and fever. Tachycardia, itching, dizziness, myalgia, fatigue, nausea and headaches were also observed.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 05 Dec 2017

Results of a study conducted by the Chinese University of Hong Kong (CUHK) revealed that patients who recovered from hepatitis B virus (HBV) infection are still at risk for hepatocellular carcinoma (HCC). 

Dr. Joseph Delano Fule Robles, 11 Dec 2017

Societies that value autonomy and harmony tend to have higher alcohol consumption as compared with more conservative societies that value hierarchy and embeddedness, a recent study has shown. 

Tristan Manalac, 10 Dec 2017
Mirizzi Syndrome (MS) is a rare medical phenomenon in Singapore and its accurate diagnosis remains a challenge, reports a recent study, which also shows that less than 75 percent of patients are accurately diagnosed prior to surgery.
Kathlin Ambrose, 17 Apr 2015
Timely treatment of autoimmune hepatitis (AIH) is life saving, says an expert in autoimmune liver diseases.